StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Stock analysts at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report released on Tuesday. The firm set a “hold” rating on the stock.

Oncternal Therapeutics Stock Performance

Shares of NASDAQ:ONCT opened at $0.53 on Tuesday. Oncternal Therapeutics has a 52 week low of $0.53 and a 52 week high of $13.14. The company has a market capitalization of $1.56 million, a PE ratio of -0.05 and a beta of 1.18. The company has a 50 day moving average price of $0.75 and a two-hundred day moving average price of $2.82.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.